External
Repatriation Medical Authority Statement

Morbid obesity - Treatment with a drug as specified for morbid obesity Factor

Last reviewed for CCPS 17 December 2003.

Investigative Documents

Medical Report - Drug Treatment as a Cause of Morbid Obesity [MR9307]

Preliminary questions [33366]

33386

there is some evidence that treatment with a drug as specified for morbid obesity may be a factor in the development of morbid obesity.

33387 the veteran has undergone treatment with a drug as specified for morbid obesity at some time.

33388

the drug specified for morbid obesity with which the veteran was being treated, was able to be ceased or substituted.

33389

the veteran underwent treatment with the drug as specified for morbid obesity, which drug could not be ceased or substituted, at the time of the clinical onset of morbid obesity.

33390

the treatment with the drug as specified for morbid obesity at the time of the clinical onset of morbid obesity, which drug could not be ceased or substituted, was for an illness or injury which is identifiable.

33391 — the veteran has established the causal connection between the treatment with a drug as specified for morbid obesity and VEA service for the clinical onset of morbid obesity.

33392 — the veteran has established the causal connection between the treatment with a drug as specified for morbid obesity and operational service for the clinical onset of morbid obesity.

or

33393 — the veteran has established the causal connection between the treatment with a drug as specified for morbid obesity and eligible service for the clinical onset of morbid obesity.

Clinical onset and operational service [33392]

33394 — the identified illness or injury, for which the veteran underwent treatment with a drug as specified for morbid obesity, which drug could not be ceased or substituted, is causally related to operational service.

Clinical onset and eligible service [33393]

33395 — the identified illness or injury, for which the veteran underwent treatment with a drug as specified for morbid obesity, which drug could not be ceased or substituted, is causally related to eligible service.